Annexon, Inc. (ANNX)
Annexon is a biopharmaceutical company developing targeted immunotherapies for neuroinflammatory diseases of the body, brain and eye. It last closed at $3.47 on Nov 17, down 2.80% on the day. The average 12-month price target from 2 analysts is $20.00 (+476.4% from the last close), with a high of $25.00 and a low of $15.00. Over the past 90 days StreetAlpha recorded 1 whale options trade in ANNX, 100% of them bullish and 0% bearish. In the past 30 days there were 2 dark pool prints totaling $308K, the largest $170K.
Key Stats
Last 12 monthsNot reported for this period.
From ANNX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on ANNX in the past 90 days. The average target is $20.00, with a high of $25.00 and a low of $15.00, compared with the last close of $3.47.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 19 | HC Wainwright & Co. | Maintained | Buy | $25 |
| Sep 30 | JP Morgan | Target raised | Buy | $14 → $15 |
| Sep 1 | JP Morgan | Maintained | Buy | $14 |
| Jul 21 | Citizens | Initiated | Sell | $3 |
| Jul 15 | Needham | Maintained | Buy | $25 |
Technical Analysis
The stock is 14% below its 20 day and 15% below its 50 day average. It is 46% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot S1 at $3.36, and the nearest resistance the Pivot at $3.48.
| RSI (14) | 35.73 | Weak, oversold below 30 | Neutral |
| MACD | -0.06 | Below its signal line | Bearish |
| Stochastic | 13.2 | Near the bottom of its range | Oversold |
| ADX (14) | 15.5 | No clear trend | |
| Williams %R | -90.9 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -191.1 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −17.2% | Change over 10 sessions | Bearish |
| ATR (14) | $0.26 | Typical daily range, 7.6% of price |
| RSI (14) | 38.86 | Weak, oversold below 30 | Neutral |
| MACD | -0.38 | Below its signal line | Bearish |
| Stochastic | 22.0 | Middle of its range | Neutral |
| ADX (14) | 21.4 | Weak trend | |
| Williams %R | -95.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -96.7 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −11.9% | Change over 10 sessions | Bearish |
| ATR (14) | $0.68 | Typical daily range, 19.6% of price |
What happened before
See how ANNX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ANNX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in ANNX in the last 90 days.
Dark Pool
30DANNX Institutional Ownership
Full report →- ●112 buying vs 98 selling
- ▲Shares held by funds +10.0%
- ▼Funds holding -12
- ●Superinvestors: 2 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 205 | 217 | −5.5% |
| In funds' top 10 | 4 | 4 | 0.0% |
| Held by funds | – | – | – |
| New / increased | 31 / 81 | 29 / 79 | +3.7% |
| Reduced / sold out | 58 / 40 | 79 / 28 | −8.4% |
| Put/call ratio | 0.68 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANNX is in one of them and how their past ANNX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ANNX in an article yet. Here's the latest on the wider market.
About Annexon
Annexon is a biopharmaceutical company based in Brisbane, California. It develops drug candidates that target C1q, an early step in the classical complement pathway, a part of the immune system that can drive inflammation and tissue damage. Its main programs address neuroinflammatory diseases of the body, brain and eye, including Guillain-Barré Syndrome, geographic atrophy and autoimmune conditions. The company is developing these treatments for patients and does not yet have an approved product.
- Headquarters
- Brisbane, CA



